{
  "dataset": {
    "name": "pharmacy_copilot_pharmacist_eval_v1",
    "description": "Gold pharmacist scenarios for LLM evaluation (enriched for deterministic scoring).",
    "version": "1.2.0"
  },
  "metadata": {
    "question_count": 13,
    "evaluation_time": 48.275120973587036
  },
  "aggregated_metrics": {
    "retrieval": {
      "recall_at_k": {
        "1": 0.6538461538461539,
        "3": 0.9230769230769231,
        "5": 0.9230769230769231,
        "10": 0.9230769230769231,
        "20": 0.9230769230769231
      },
      "precision_at_k": {
        "1": 0.9230769230769231,
        "3": 0.5897435897435896,
        "5": 0.5897435897435896,
        "10": 0.5897435897435896,
        "20": 0.5897435897435896
      },
      "mean_reciprocal_rank": 0.9230769230769231,
      "average_precision": 0.9230769230769231,
      "ndcg_at_k": {
        "1": 0.9230769230769231,
        "3": 0.9230769230769231,
        "5": 0.9230769230769231,
        "10": 0.9230769230769231,
        "20": 0.9230769230769231
      },
      "essential_recall_at_k": {
        "1": 0.9230769230769231,
        "3": 0.9230769230769231,
        "5": 0.9230769230769231,
        "10": 0.9230769230769231,
        "20": 0.9230769230769231
      },
      "first_relevant_rank": 0.9230769230769231,
      "total_relevant": 19,
      "total_essential": 12
    },
    "qa": {
      "bleu_score": 0.024703242770268526,
      "rouge_1_f1": 0.3234550387093805,
      "rouge_2_f1": 0.15331854252196428,
      "rouge_l_f1": 0.2334278865830515,
      "semantic_similarity": 0.6051911069796636,
      "key_points_covered": 0.25274725274725274,
      "key_points_found": [],
      "key_points_missing": [],
      "answer_length": 30,
      "has_answer": true,
      "factual_accuracy": null,
      "helpfulness": null
    }
  },
  "failure_cases": [
    {
      "question_id": "q001",
      "question": "5-year-old (18 kg) with acute otitis media. What is the amoxicillin dose and volume using 400 mg/5 mL suspension?",
      "failure_types": [
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-amoxicillin-2018#dosage",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#peds",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#adult-sinusitis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-amoxicillin-2018#dosage",
        "lexi-amoxicillin-2018#peds"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":810,\"volume_per_dose_mL\":10,\"frequency\":\"q12h\",\"max_daily_mg\":4000,\"rounding\":\"Rounded from 10.1 mL to 10 mL for practical measurement\",\"calc_rule\":\"90 mg/kg/day ÷ 2 doses = 45 mg/kg/dose; 18 kg × 45 mg/kg = 810 mg/dose; volume = 810 mg ÷ (80 mg/mL)\",\"citations\":[\"lexi-amoxicillin-2018#dosage\",\"lexi-amoxicillin-2018#peds\"],\"notes\":\"High-dose amoxicillin regimen for AOM using 400 mg/5 mL suspension with practical volume rounding per guidance.\"}",
      "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
      "key_points_missing": [
        "Uses high-dose 80–90 mg/kg/day regimen",
        "Per-dose ≈810 mg for 18 kg",
        "Max daily 4 g acknowledged",
        "No renal adjustment if normal function",
        "Cites pediatric dosage section"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.018920041126127753,
        "rouge_1_f1": 0.4324324324324324,
        "rouge_2_f1": 0.23853211009174313,
        "rouge_l_f1": 0.2522522522522523,
        "semantic_similarity": 0.7812321186065674,
        "key_points_covered": 0.2857142857142857,
        "key_points_found": [
          "BID (q12h) frequency",
          "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK"
        ],
        "key_points_missing": [
          "Uses high-dose 80–90 mg/kg/day regimen",
          "Per-dose ≈810 mg for 18 kg",
          "Max daily 4 g acknowledged",
          "No renal adjustment if normal function",
          "Cites pediatric dosage section"
        ],
        "answer_length": 47,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "medium",
      "notes": null
    },
    {
      "question_id": "q002",
      "question": "12 kg child with fever: acetaminophen dose and volume using 160 mg/5 mL?",
      "failure_types": [
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#max",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#rectal",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-acetaminophen-2018#max",
        "lexi-acetaminophen-2018#peds-dosing"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":180,\"volume_per_dose_mL\":5.6,\"frequency\":\"q6h\",\"max_daily_mg\":900,\"rounding\":\"Rounded volume from 5.625 mL to 5.6 mL\",\"calc_rule\":\"15 mg/kg/dose × 12 kg = 180 mg; max 75 mg/kg/day = 900 mg\",\"citations\":[\"lexi-acetaminophen-2018#peds-dosing\",\"lexi-acetaminophen-2018#max\"],\"notes\":\"Oral liquid acetaminophen dosed at 15 mg/kg/dose using 160 mg/5 mL concentration for fever management.\"}",
      "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
      "key_points_missing": [
        "Per-dose 15 mg/kg used",
        "q4–6h acceptable; target q6h in calc",
        "Volume ≈5.625 mL from 32 mg/mL",
        "Daily max 75 mg/kg/day and ≤4 g",
        "Pediatric dosing section cited"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.045366131955229226,
        "rouge_1_f1": 0.49090909090909085,
        "rouge_2_f1": 0.33333333333333326,
        "rouge_l_f1": 0.3090909090909091,
        "semantic_similarity": 0.7578736543655396,
        "key_points_covered": 0.16666666666666666,
        "key_points_found": [
          "180 mg per dose for 12 kg"
        ],
        "key_points_missing": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g",
          "Pediatric dosing section cited"
        ],
        "answer_length": 35,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "medium",
      "notes": null
    },
    {
      "question_id": "q003",
      "question": "12 kg child with fever: ibuprofen dose and volume using 100 mg/5 mL?",
      "failure_types": [
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#max",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#adult-capsules",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-ibuprofen-2018#max",
        "lexi-ibuprofen-2018#peds-dosing"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":120,\"volume_per_dose_mL\":6.0,\"frequency\":\"q6-8h\",\"max_daily_mg\":480,\"rounding\":\"Rounded to nearest 0.5 mL\",\"calc_rule\":\"10 mg/kg/dose × 12 kg = 120 mg; volume = 120 mg ÷ (100 mg/5 mL) = 6 mL; max 40 mg/kg/day = 480 mg\",\"citations\":[\"lexi-ibuprofen-2018#peds-dosing\",\"lexi-ibuprofen-2018#max\"],\"notes\":\"Weight-based dosing using 100 mg/5 mL suspension with caution in dehydration or renal risk.\"}",
      "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
      "key_points_missing": [
        "10 mg/kg per dose",
        "q6–8h frequency",
        "120 mg per dose for 12 kg",
        "6 mL at 20 mg/mL",
        "Contraindication: <6 months; caution renal/dehydration"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.05650942013370337,
        "rouge_1_f1": 0.5045045045045045,
        "rouge_2_f1": 0.3119266055045872,
        "rouge_l_f1": 0.34234234234234234,
        "semantic_similarity": 0.7421085238456726,
        "key_points_covered": 0.16666666666666666,
        "key_points_found": [
          "Max 40 mg/kg/day (480 mg)"
        ],
        "key_points_missing": [
          "10 mg/kg per dose",
          "q6–8h frequency",
          "120 mg per dose for 12 kg",
          "6 mL at 20 mg/mL",
          "Contraindication: <6 months; caution renal/dehydration"
        ],
        "answer_length": 42,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "medium",
      "notes": null
    },
    {
      "question_id": "q004",
      "question": "Elderly patient with nonvalvular AF: 82 years, 58 kg, SCr 1.6 mg/dL. What apixaban dose?",
      "failure_types": [
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-apixaban-2018#ddi",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-apixaban-2018#vte",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-apixaban-2018#ddi",
        "lexi-apixaban-2018#dosing-nvaf"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":2.5,\"volume_per_dose_mL\":null,\"frequency\":\"q12h\",\"max_daily_mg\":5,\"rounding\":\"No rounding needed for tablet dose\",\"calc_rule\":\"Meets 2 of 3 criteria for dose reduction: age ≥80y (82y), weight ≤60kg (58kg), SCr ≥1.5mg/dL (1.6mg/dL)\",\"citations\":[\"lexi-apixaban-2018#dosing-nvaf\"],\"notes\":\"Reduced dose of 2.5mg tablets twice daily indicated due to meeting multiple criteria for dose reduction in NVAF.\"}",
      "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
      "key_points_missing": [
        "Final dose 2.5 mg BID",
        "Interaction caveat: strong CYP3A4/P-gp",
        "Hepatic impairment caution"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.03287730234365174,
        "rouge_1_f1": 0.26804123711340205,
        "rouge_2_f1": 0.10526315789473684,
        "rouge_l_f1": 0.22680412371134018,
        "semantic_similarity": 0.4757928252220154,
        "key_points_covered": 0.25,
        "key_points_found": [
          "Dose reduction criteria (2 of 3)"
        ],
        "key_points_missing": [
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "answer_length": 39,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q005",
      "question": "85 kg adult with acute DVT: What is the enoxaparin treatment dose (normal renal function)?",
      "failure_types": [
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-enoxaparin-2018#dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#renal",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#prophylaxis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-enoxaparin-2018#dosing",
        "lexi-enoxaparin-2018#renal"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":85,\"volume_per_dose_mL\":0.9,\"frequency\":\"q12h\",\"max_daily_mg\":170,\"rounding\":\"Round to nearest 0.1 mL based on 100 mg/mL concentration\",\"calc_rule\":\"1 mg/kg q12h (preferred regimen) x 85 kg = 85 mg per dose\",\"citations\":[\"lexi-enoxaparin-2018#dosing\"],\"notes\":\"Preferred regimen is 1 mg/kg q12h for acute DVT with normal renal function, with 1.5 mg/kg daily as an alternative.\"}",
      "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
      "key_points_missing": [
        "Renal adjustment for CrCl <30"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.03887336246346367,
        "rouge_1_f1": 0.4077669902912622,
        "rouge_2_f1": 0.21782178217821782,
        "rouge_l_f1": 0.2912621359223301,
        "semantic_similarity": 0.730822741985321,
        "key_points_covered": 0.75,
        "key_points_found": [
          "1 mg/kg q12h primary regimen",
          "Alternative 1.5 mg/kg q24h",
          "Per-dose 85 mg for 85 kg"
        ],
        "key_points_missing": [
          "Renal adjustment for CrCl <30"
        ],
        "answer_length": 41,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "medium",
      "notes": null
    },
    {
      "question_id": "q006",
      "question": "Type 2 diabetes patient with eGFR 28 mL/min/1.73 m². Can we use metformin?",
      "failure_types": [
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-metformin-2018#renal",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-metformin-2018#contra",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-metformin-2018#old-crcl60",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-metformin-2018#contra",
        "lexi-metformin-2018#renal"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"n/a\",\"max_daily_mg\":null,\"rounding\":\"n/a\",\"calc_rule\":\"eGFR <30 mL/min/1.73m² = contraindicated\",\"citations\":[\"lexi-metformin-2018#renal\"],\"notes\":\"Metformin is contraindicated in this patient with eGFR 28 mL/min/1.73m² due to risk of lactic acidosis.\"}",
      "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
      "key_points_missing": [
        "30–45: avoid initiation; if continuing, reduce & monitor",
        "Hepatic impairment: avoid (lactic acidosis risk)"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.013186148017665336,
        "rouge_1_f1": 0.13333333333333333,
        "rouge_2_f1": 0.027397260273972605,
        "rouge_l_f1": 0.08,
        "semantic_similarity": 0.5471715331077576,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Contraindicated if eGFR <30"
        ],
        "key_points_missing": [
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "answer_length": 20,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q007",
      "question": "Uncomplicated cystitis: Should we use nitrofurantoin if eGFR is 25?",
      "failure_types": [
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-nitrofurantoin-2018#renal",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#contra",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#prophylaxis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-nitrofurantoin-2018#contra",
        "lexi-nitrofurantoin-2018#renal"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"\",\"max_daily_mg\":null,\"rounding\":\"Not applicable - contraindicated\",\"calc_rule\":\"Contraindicated if eGFR <30 mL/min\",\"citations\":[\"lexi-nitrofurantoin-2018#renal\",\"lexi-nitrofurantoin-2018#contra\"],\"notes\":\"Nitrofurantoin is contraindicated at eGFR 25 mL/min due to inadequate urinary concentrations and increased toxicity risk.\"}",
      "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
      "key_points_missing": [
        "Avoid if eGFR/CrCl <30",
        "Rationale: efficacy/toxicity",
        "List common contraindications where relevant"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.023310461063598017,
        "rouge_1_f1": 0.3142857142857142,
        "rouge_2_f1": 0.14705882352941177,
        "rouge_l_f1": 0.2857142857142857,
        "semantic_similarity": 0.7304202914237976,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Avoid if eGFR/CrCl <30",
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "answer_length": 23,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "medium",
      "notes": null
    },
    {
      "question_id": "q008",
      "question": "Patient on warfarin needs TMP-SMX for UTI. Any interaction and what should we do?",
      "failure_types": [
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-warfarin-2018#ddi-cephalexin",
          "score": 0.0,
          "rank": 2
        }
      ],
      "relevant_chunks_found": [
        "lexi-warfarin-2018#ddi-tmp-smx"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"n/a\",\"max_daily_mg\":null,\"rounding\":\"n/a\",\"calc_rule\":\"Drug interaction via CYP2C9 inhibition and gut flora changes\",\"citations\":[\"lexi-warfarin-2018#ddi-tmp-smx\"],\"notes\":\"TMP-SMX markedly increases warfarin effect requiring warfarin dose reduction and increased INR monitoring, with preference for alternative antibiotics.\"}",
      "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
      "key_points_missing": [
        "Severity: major",
        "Action: avoid or close INR monitoring with dose reduction"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.009203532683299362,
        "rouge_1_f1": 0.29333333333333333,
        "rouge_2_f1": 0.136986301369863,
        "rouge_l_f1": 0.21333333333333335,
        "semantic_similarity": 0.5828671455383301,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Mechanism: CYP2C9 inhibition + gut flora"
        ],
        "key_points_missing": [
          "Severity: major",
          "Action: avoid or close INR monitoring with dose reduction"
        ],
        "answer_length": 26,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q009",
      "question": "Patient on atorvastatin needs clarithromycin. What’s the risk and action?",
      "failure_types": [
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-azithro",
          "score": 0.0,
          "rank": 2
        }
      ],
      "relevant_chunks_found": [
        "lexi-atorvastatin-2018#ddi-macrolides"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"hold\",\"max_daily_mg\":null,\"rounding\":\"not applicable\",\"calc_rule\":\"hold atorvastatin during clarithromycin due to CYP3A4 inhibition; if unavoidable use lowest dose with monitoring\",\"citations\":[\"lexi-atorvastatin-2018#ddi-macrolides\"],\"notes\":\"Major interaction increases myopathy/rhabdomyolysis risk through strong CYP3A4 inhibition.\"}",
      "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
      "key_points_missing": [
        "Severity: major"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.01968294124523931,
        "rouge_1_f1": 0.35135135135135137,
        "rouge_2_f1": 0.1388888888888889,
        "rouge_l_f1": 0.18918918918918917,
        "semantic_similarity": 0.6204959154129028,
        "key_points_covered": 0.6666666666666666,
        "key_points_found": [
          "Mechanism: strong CYP3A4 inhibition",
          "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
        ],
        "key_points_missing": [
          "Severity: major"
        ],
        "answer_length": 24,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q010",
      "question": "Starting linezolid in a patient on sertraline. Is this safe?",
      "failure_types": [
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-linezolid-2018#ddi-ssri",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-linezolid-2018#ddi-penicillins",
          "score": 0.0,
          "rank": 2
        }
      ],
      "relevant_chunks_found": [
        "lexi-linezolid-2018#ddi-ssri"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"n/a\",\"max_daily_mg\":null,\"rounding\":\"n/a\",\"calc_rule\":\"Contraindicated due to MAOI activity unless benefits outweigh risks\",\"citations\":[\"lexi-linezolid-2018#ddi-ssri\"],\"notes\":\"Avoid combination due to serotonin syndrome risk; if necessary, withhold SSRI and monitor closely.\"}",
      "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
      "key_points_missing": [
        "Mechanism: MAOI activity → ↑serotonin",
        "Severity: major",
        "Action: avoid; or stop SSRI/close monitoring if unavoidable"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.02709687095237191,
        "rouge_1_f1": 0.410958904109589,
        "rouge_2_f1": 0.14084507042253522,
        "rouge_l_f1": 0.24657534246575344,
        "semantic_similarity": 0.5318275094032288,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "answer_length": 22,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q011",
      "question": "Patient on digoxin will start amiodarone. What’s the interaction management?",
      "failure_types": [
        "retrieval_irrelevant",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-digoxin-2018#ddi-amio",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-digoxin-2018#ddi-verapamil",
          "score": 0.0,
          "rank": 2
        }
      ],
      "relevant_chunks_found": [
        "lexi-digoxin-2018#ddi-amio"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"maintain current\",\"max_daily_mg\":null,\"rounding\":\"reduce current dose by 30-50%\",\"calc_rule\":\"reduce existing digoxin dose by 30-50% due to P-glycoprotein inhibition\",\"citations\":[\"lexi-digoxin-2018#ddi-amio\"],\"notes\":\"Reduce digoxin dose by 30-50% when starting amiodarone and monitor digoxin levels, renal function, and ECG.\"}",
      "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
      "key_points_missing": [
        "Mechanism: P-gp inhibition → ↑digoxin",
        "Severity: major"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.030188043146318764,
        "rouge_1_f1": 0.3116883116883117,
        "rouge_2_f1": 0.16000000000000003,
        "rouge_l_f1": 0.3116883116883117,
        "semantic_similarity": 0.7014154195785522,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Action: reduce dose ~30–50% + monitor levels and ECG"
        ],
        "key_points_missing": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major"
        ],
        "answer_length": 30,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "medium",
      "notes": null
    },
    {
      "question_id": "q012",
      "question": "COVID-19 patient asks for Paxlovid dosing and interaction checks.",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "kb-scope-2018#covid-absent",
          "score": 0.0,
          "rank": 1
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"\",\"max_daily_mg\":null,\"rounding\":\"Not applicable - insufficient data\",\"calc_rule\":\"Cannot calculate - predates COVID-19 therapies\",\"citations\":[\"kb-scope-2018#covid-absent\"],\"notes\":\"Knowledge base predates COVID-19 therapies including Paxlovid (nirmatrelvir/ritonavir); refer to current clinical guidance and pharmacist.\"}",
      "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
      "key_points_missing": [
        "Explicit abstention",
        "Sets recency_risk = true",
        "Advises pharmacist/current guidance"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 0,
        "total_essential": 0
      },
      "qa_metrics": {
        "bleu_score": 0.0028418842662913846,
        "rouge_1_f1": 0.18461538461538463,
        "rouge_2_f1": 0.0,
        "rouge_l_f1": 0.18461538461538463,
        "semantic_similarity": 0.40756627917289734,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "answer_length": 24,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q013",
      "question": "What is the current first-line pharmacologic therapy per latest hypertension guidelines?",
      "failure_types": [
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-hypertension-2014#jnc8",
          "score": 0.0,
          "rank": 1
        }
      ],
      "relevant_chunks_found": [
        "lexi-hypertension-2014#jnc8"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"\",\"max_daily_mg\":null,\"rounding\":\"Not applicable\",\"calc_rule\":\"No current dosing available\",\"citations\":[\"lexi-hypertension-2014#jnc8\"],\"notes\":\"Cannot provide current first-line therapy as available guideline data from JNC8 (2014) is outdated.\"}",
      "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
      "key_points_missing": [
        "Explicit abstention for ‘current’ guideline ask",
        "Recognize JNC8 (2014) is outdated for ‘current’",
        "Sets recency_risk = true"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0030860166165309253,
        "rouge_1_f1": 0.10169491525423728,
        "rouge_2_f1": 0.03508771929824561,
        "rouge_l_f1": 0.10169491525423728,
        "semantic_similarity": 0.2578904330730438,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Explicit abstention for ‘current’ guideline ask",
          "Recognize JNC8 (2014) is outdated for ‘current’",
          "Sets recency_risk = true"
        ],
        "answer_length": 18,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "high",
      "notes": null
    }
  ],
  "questions": [
    {
      "question_id": "q001",
      "question": {
        "id": "q001",
        "question": "5-year-old (18 kg) with acute otitis media. What is the amoxicillin dose and volume using 400 mg/5 mL suspension?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
        "answer_key_points": [
          "Uses high-dose 80–90 mg/kg/day regimen",
          "BID (q12h) frequency",
          "Per-dose ≈810 mg for 18 kg",
          "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK",
          "Max daily 4 g acknowledged",
          "No renal adjustment if normal function",
          "Cites pediatric dosage section"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-amoxicillin-2018#dosage",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#peds",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "amoxicillin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 810,
          "doses_per_day": 2,
          "total_daily_mg": 1620,
          "calc_rule": "90 mg/kg/day divided q12h",
          "max_daily_mg": 4000,
          "volume_per_dose_mL": 10.125,
          "rounding": {
            "to": "10 mL per dose",
            "basis": "80 mg/mL (400 mg/5 mL)"
          },
          "renal_adjustment": "none if normal renal function",
          "hepatic_adjustment": "none specified",
          "contraindications": [],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-amoxicillin-2018#dosage",
            "lexi-amoxicillin-2018#peds"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-amoxicillin-2018#dosage",
            "role": "support",
            "text": "Pediatric AOM first-line: amoxicillin 80–90 mg/kg/day PO divided q12h for 5–10 days; typical max daily dose ~4,000 mg."
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#peds",
            "role": "support",
            "text": "Amoxicillin oral suspension 400 mg/5 mL = 80 mg/mL; use oral syringe; rounding to practical mL is acceptable."
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#adult-sinusitis",
            "role": "distractor",
            "text": "Adult acute bacterial sinusitis regimens (e.g., 500 mg TID or 875 mg BID) differ from pediatric AOM dosing."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-amoxicillin-2018#dosage",
            "lexi-amoxicillin-2018#peds"
          ],
          "disallowed_chunk_ids": [
            "lexi-amoxicillin-2018#adult-sinusitis"
          ]
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":810,\"volume_per_dose_mL\":10,\"frequency\":\"q12h\",\"max_daily_mg\":4000,\"rounding\":\"Rounded from 10.1 mL to 10 mL for practical measurement\",\"calc_rule\":\"90 mg/kg/day ÷ 2 doses = 45 mg/kg/dose; 18 kg × 45 mg/kg = 810 mg/dose; volume = 810 mg ÷ (80 mg/mL)\",\"citations\":[\"lexi-amoxicillin-2018#dosage\",\"lexi-amoxicillin-2018#peds\"],\"notes\":\"High-dose amoxicillin regimen for AOM using 400 mg/5 mL suspension with practical volume rounding per guidance.\"}",
      "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.018920041126127753,
        "rouge_1_f1": 0.4324324324324324,
        "rouge_2_f1": 0.23853211009174313,
        "rouge_l_f1": 0.2522522522522523,
        "semantic_similarity": 0.7812321186065674,
        "key_points_covered": 0.2857142857142857,
        "key_points_found": [
          "BID (q12h) frequency",
          "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK"
        ],
        "key_points_missing": [
          "Uses high-dose 80–90 mg/kg/day regimen",
          "Per-dose ≈810 mg for 18 kg",
          "Max daily 4 g acknowledged",
          "No renal adjustment if normal function",
          "Cites pediatric dosage section"
        ],
        "answer_length": 47,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-amoxicillin-2018#dosage",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#peds",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#adult-sinusitis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-amoxicillin-2018#dosage",
          "role": "support",
          "text": "Pediatric AOM first-line: amoxicillin 80–90 mg/kg/day PO divided q12h for 5–10 days; typical max daily dose ~4,000 mg."
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#peds",
          "role": "support",
          "text": "Amoxicillin oral suspension 400 mg/5 mL = 80 mg/mL; use oral syringe; rounding to practical mL is acceptable."
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#adult-sinusitis",
          "role": "distractor",
          "text": "Adult acute bacterial sinusitis regimens (e.g., 500 mg TID or 875 mg BID) differ from pediatric AOM dosing."
        }
      ],
      "failure_analysis": {
        "question_id": "q001",
        "question": "5-year-old (18 kg) with acute otitis media. What is the amoxicillin dose and volume using 400 mg/5 mL suspension?",
        "failure_types": [
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-amoxicillin-2018#dosage",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#peds",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#adult-sinusitis",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-amoxicillin-2018#dosage",
          "lexi-amoxicillin-2018#peds"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":810,\"volume_per_dose_mL\":10,\"frequency\":\"q12h\",\"max_daily_mg\":4000,\"rounding\":\"Rounded from 10.1 mL to 10 mL for practical measurement\",\"calc_rule\":\"90 mg/kg/day ÷ 2 doses = 45 mg/kg/dose; 18 kg × 45 mg/kg = 810 mg/dose; volume = 810 mg ÷ (80 mg/mL)\",\"citations\":[\"lexi-amoxicillin-2018#dosage\",\"lexi-amoxicillin-2018#peds\"],\"notes\":\"High-dose amoxicillin regimen for AOM using 400 mg/5 mL suspension with practical volume rounding per guidance.\"}",
        "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
        "key_points_missing": [
          "Uses high-dose 80–90 mg/kg/day regimen",
          "Per-dose ≈810 mg for 18 kg",
          "Max daily 4 g acknowledged",
          "No renal adjustment if normal function",
          "Cites pediatric dosage section"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.018920041126127753,
          "rouge_1_f1": 0.4324324324324324,
          "rouge_2_f1": 0.23853211009174313,
          "rouge_l_f1": 0.2522522522522523,
          "semantic_similarity": 0.7812321186065674,
          "key_points_covered": 0.2857142857142857,
          "key_points_found": [
            "BID (q12h) frequency",
            "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK"
          ],
          "key_points_missing": [
            "Uses high-dose 80–90 mg/kg/day regimen",
            "Per-dose ≈810 mg for 18 kg",
            "Max daily 4 g acknowledged",
            "No renal adjustment if normal function",
            "Cites pediatric dosage section"
          ],
          "answer_length": 47,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "medium",
        "notes": null
      }
    },
    {
      "question_id": "q002",
      "question": {
        "id": "q002",
        "question": "12 kg child with fever: acetaminophen dose and volume using 160 mg/5 mL?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
        "answer_key_points": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "180 mg per dose for 12 kg",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g",
          "Pediatric dosing section cited"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#max",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "acetaminophen"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 180,
          "doses_per_day": 4,
          "total_daily_mg": 720,
          "calc_rule": "15 mg/kg/dose q6h (10–15 mg/kg q4–6h acceptable)",
          "max_daily_mg": 900,
          "volume_per_dose_mL": 5.625,
          "rounding": {
            "to": "5.6 mL",
            "basis": "32 mg/mL (160 mg/5 mL)"
          },
          "renal_adjustment": "none for standard antipyresis",
          "hepatic_adjustment": "use caution in hepatic impairment",
          "contraindications": [],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-acetaminophen-2018#peds-dosing",
            "lexi-acetaminophen-2018#max"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
            "role": "support",
            "text": "Acetaminophen 10–15 mg/kg/dose PO q4–6h PRN fever/pain; do not exceed 75 mg/kg/day or 4,000 mg/day; ~5 doses/24h."
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#max",
            "role": "support",
            "text": "Common liquid: 160 mg/5 mL (32 mg/mL). Use weight-based dosing and state per-dose mL."
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#rectal",
            "role": "distractor",
            "text": "Rectal suppository dosing differs from oral liquids and is not used for this calculation."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-acetaminophen-2018#peds-dosing",
            "lexi-acetaminophen-2018#max"
          ],
          "disallowed_chunk_ids": [
            "lexi-acetaminophen-2018#rectal"
          ]
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":180,\"volume_per_dose_mL\":5.6,\"frequency\":\"q6h\",\"max_daily_mg\":900,\"rounding\":\"Rounded volume from 5.625 mL to 5.6 mL\",\"calc_rule\":\"15 mg/kg/dose × 12 kg = 180 mg; max 75 mg/kg/day = 900 mg\",\"citations\":[\"lexi-acetaminophen-2018#peds-dosing\",\"lexi-acetaminophen-2018#max\"],\"notes\":\"Oral liquid acetaminophen dosed at 15 mg/kg/dose using 160 mg/5 mL concentration for fever management.\"}",
      "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.045366131955229226,
        "rouge_1_f1": 0.49090909090909085,
        "rouge_2_f1": 0.33333333333333326,
        "rouge_l_f1": 0.3090909090909091,
        "semantic_similarity": 0.7578736543655396,
        "key_points_covered": 0.16666666666666666,
        "key_points_found": [
          "180 mg per dose for 12 kg"
        ],
        "key_points_missing": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g",
          "Pediatric dosing section cited"
        ],
        "answer_length": 35,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#max",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#rectal",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
          "role": "support",
          "text": "Acetaminophen 10–15 mg/kg/dose PO q4–6h PRN fever/pain; do not exceed 75 mg/kg/day or 4,000 mg/day; ~5 doses/24h."
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#max",
          "role": "support",
          "text": "Common liquid: 160 mg/5 mL (32 mg/mL). Use weight-based dosing and state per-dose mL."
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#rectal",
          "role": "distractor",
          "text": "Rectal suppository dosing differs from oral liquids and is not used for this calculation."
        }
      ],
      "failure_analysis": {
        "question_id": "q002",
        "question": "12 kg child with fever: acetaminophen dose and volume using 160 mg/5 mL?",
        "failure_types": [
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#max",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#rectal",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-acetaminophen-2018#max",
          "lexi-acetaminophen-2018#peds-dosing"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":180,\"volume_per_dose_mL\":5.6,\"frequency\":\"q6h\",\"max_daily_mg\":900,\"rounding\":\"Rounded volume from 5.625 mL to 5.6 mL\",\"calc_rule\":\"15 mg/kg/dose × 12 kg = 180 mg; max 75 mg/kg/day = 900 mg\",\"citations\":[\"lexi-acetaminophen-2018#peds-dosing\",\"lexi-acetaminophen-2018#max\"],\"notes\":\"Oral liquid acetaminophen dosed at 15 mg/kg/dose using 160 mg/5 mL concentration for fever management.\"}",
        "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
        "key_points_missing": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g",
          "Pediatric dosing section cited"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.045366131955229226,
          "rouge_1_f1": 0.49090909090909085,
          "rouge_2_f1": 0.33333333333333326,
          "rouge_l_f1": 0.3090909090909091,
          "semantic_similarity": 0.7578736543655396,
          "key_points_covered": 0.16666666666666666,
          "key_points_found": [
            "180 mg per dose for 12 kg"
          ],
          "key_points_missing": [
            "Per-dose 15 mg/kg used",
            "q4–6h acceptable; target q6h in calc",
            "Volume ≈5.625 mL from 32 mg/mL",
            "Daily max 75 mg/kg/day and ≤4 g",
            "Pediatric dosing section cited"
          ],
          "answer_length": 35,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "medium",
        "notes": null
      }
    },
    {
      "question_id": "q003",
      "question": {
        "id": "q003",
        "question": "12 kg child with fever: ibuprofen dose and volume using 100 mg/5 mL?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
        "answer_key_points": [
          "10 mg/kg per dose",
          "q6–8h frequency",
          "120 mg per dose for 12 kg",
          "6 mL at 20 mg/mL",
          "Max 40 mg/kg/day (480 mg)",
          "Contraindication: <6 months; caution renal/dehydration"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#max",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "ibuprofen"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 120,
          "doses_per_day": 4,
          "total_daily_mg": 480,
          "calc_rule": "10 mg/kg/dose q6–8h; max 40 mg/kg/day",
          "max_daily_mg": 480,
          "volume_per_dose_mL": 6.0,
          "rounding": {
            "to": "6 mL",
            "basis": "20 mg/mL (100 mg/5 mL)"
          },
          "renal_adjustment": "avoid in significant renal impairment/dehydration",
          "hepatic_adjustment": "use caution",
          "contraindications": [
            "<6 months age",
            "active GI bleed"
          ],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-ibuprofen-2018#peds-dosing",
            "lexi-ibuprofen-2018#max"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
            "role": "support",
            "text": "Ibuprofen 10 mg/kg/dose PO q6–8h PRN; maximum 40 mg/kg/day; avoid in dehydration or significant renal risk."
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#max",
            "role": "support",
            "text": "Oral suspension 100 mg/5 mL (20 mg/mL); compute per-dose mL from weight-based mg."
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#adult-capsules",
            "role": "distractor",
            "text": "Adult OTC capsule labeling (200 mg) is not applicable to pediatric suspension dosing."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-ibuprofen-2018#peds-dosing",
            "lexi-ibuprofen-2018#max"
          ],
          "disallowed_chunk_ids": [
            "lexi-ibuprofen-2018#adult-capsules"
          ]
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":120,\"volume_per_dose_mL\":6.0,\"frequency\":\"q6-8h\",\"max_daily_mg\":480,\"rounding\":\"Rounded to nearest 0.5 mL\",\"calc_rule\":\"10 mg/kg/dose × 12 kg = 120 mg; volume = 120 mg ÷ (100 mg/5 mL) = 6 mL; max 40 mg/kg/day = 480 mg\",\"citations\":[\"lexi-ibuprofen-2018#peds-dosing\",\"lexi-ibuprofen-2018#max\"],\"notes\":\"Weight-based dosing using 100 mg/5 mL suspension with caution in dehydration or renal risk.\"}",
      "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.05650942013370337,
        "rouge_1_f1": 0.5045045045045045,
        "rouge_2_f1": 0.3119266055045872,
        "rouge_l_f1": 0.34234234234234234,
        "semantic_similarity": 0.7421085238456726,
        "key_points_covered": 0.16666666666666666,
        "key_points_found": [
          "Max 40 mg/kg/day (480 mg)"
        ],
        "key_points_missing": [
          "10 mg/kg per dose",
          "q6–8h frequency",
          "120 mg per dose for 12 kg",
          "6 mL at 20 mg/mL",
          "Contraindication: <6 months; caution renal/dehydration"
        ],
        "answer_length": 42,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#max",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#adult-capsules",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
          "role": "support",
          "text": "Ibuprofen 10 mg/kg/dose PO q6–8h PRN; maximum 40 mg/kg/day; avoid in dehydration or significant renal risk."
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#max",
          "role": "support",
          "text": "Oral suspension 100 mg/5 mL (20 mg/mL); compute per-dose mL from weight-based mg."
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#adult-capsules",
          "role": "distractor",
          "text": "Adult OTC capsule labeling (200 mg) is not applicable to pediatric suspension dosing."
        }
      ],
      "failure_analysis": {
        "question_id": "q003",
        "question": "12 kg child with fever: ibuprofen dose and volume using 100 mg/5 mL?",
        "failure_types": [
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#max",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#adult-capsules",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-ibuprofen-2018#max",
          "lexi-ibuprofen-2018#peds-dosing"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":120,\"volume_per_dose_mL\":6.0,\"frequency\":\"q6-8h\",\"max_daily_mg\":480,\"rounding\":\"Rounded to nearest 0.5 mL\",\"calc_rule\":\"10 mg/kg/dose × 12 kg = 120 mg; volume = 120 mg ÷ (100 mg/5 mL) = 6 mL; max 40 mg/kg/day = 480 mg\",\"citations\":[\"lexi-ibuprofen-2018#peds-dosing\",\"lexi-ibuprofen-2018#max\"],\"notes\":\"Weight-based dosing using 100 mg/5 mL suspension with caution in dehydration or renal risk.\"}",
        "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
        "key_points_missing": [
          "10 mg/kg per dose",
          "q6–8h frequency",
          "120 mg per dose for 12 kg",
          "6 mL at 20 mg/mL",
          "Contraindication: <6 months; caution renal/dehydration"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.05650942013370337,
          "rouge_1_f1": 0.5045045045045045,
          "rouge_2_f1": 0.3119266055045872,
          "rouge_l_f1": 0.34234234234234234,
          "semantic_similarity": 0.7421085238456726,
          "key_points_covered": 0.16666666666666666,
          "key_points_found": [
            "Max 40 mg/kg/day (480 mg)"
          ],
          "key_points_missing": [
            "10 mg/kg per dose",
            "q6–8h frequency",
            "120 mg per dose for 12 kg",
            "6 mL at 20 mg/mL",
            "Contraindication: <6 months; caution renal/dehydration"
          ],
          "answer_length": 42,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "medium",
        "notes": null
      }
    },
    {
      "question_id": "q004",
      "question": {
        "id": "q004",
        "question": "Elderly patient with nonvalvular AF: 82 years, 58 kg, SCr 1.6 mg/dL. What apixaban dose?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
        "answer_key_points": [
          "Dose reduction criteria (2 of 3)",
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-apixaban-2018#ddi",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "apixaban"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 2.5,
          "doses_per_day": 2,
          "total_daily_mg": 5,
          "calc_rule": "If ≥2 of {age ≥80, weight ≤60 kg, SCr ≥1.5} → 2.5 mg BID",
          "max_daily_mg": 10,
          "renal_adjustment": "criteria-based reduction as above",
          "hepatic_adjustment": "avoid in severe hepatic impairment",
          "contraindications": [
            "active bleeding"
          ],
          "interactions": [
            {
              "drug": "strong CYP3A4/P-gp inhibitors",
              "severity": "major",
              "action": "avoid or reduce/monitor"
            }
          ],
          "recency_risk": false,
          "citations": [
            "lexi-apixaban-2018#dosing-nvaf",
            "lexi-apixaban-2018#ddi"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
            "role": "support",
            "text": "NVAF: apixaban 5 mg BID; reduce to 2.5 mg BID if the patient has ≥2 of: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL."
          },
          {
            "chunk_id": "lexi-apixaban-2018#ddi",
            "role": "support",
            "text": "Avoid with strong dual CYP3A4/P-gp inhibitors/inducers; assess hepatic impairment."
          },
          {
            "chunk_id": "lexi-apixaban-2018#vte",
            "role": "distractor",
            "text": "VTE treatment: 10 mg BID x7 days then 5 mg BID—this regimen does not apply to NVAF dosing decisions."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-apixaban-2018#dosing-nvaf",
            "lexi-apixaban-2018#ddi"
          ],
          "disallowed_chunk_ids": [
            "lexi-apixaban-2018#vte"
          ]
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":2.5,\"volume_per_dose_mL\":null,\"frequency\":\"q12h\",\"max_daily_mg\":5,\"rounding\":\"No rounding needed for tablet dose\",\"calc_rule\":\"Meets 2 of 3 criteria for dose reduction: age ≥80y (82y), weight ≤60kg (58kg), SCr ≥1.5mg/dL (1.6mg/dL)\",\"citations\":[\"lexi-apixaban-2018#dosing-nvaf\"],\"notes\":\"Reduced dose of 2.5mg tablets twice daily indicated due to meeting multiple criteria for dose reduction in NVAF.\"}",
      "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.03287730234365174,
        "rouge_1_f1": 0.26804123711340205,
        "rouge_2_f1": 0.10526315789473684,
        "rouge_l_f1": 0.22680412371134018,
        "semantic_similarity": 0.4757928252220154,
        "key_points_covered": 0.25,
        "key_points_found": [
          "Dose reduction criteria (2 of 3)"
        ],
        "key_points_missing": [
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "answer_length": 39,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-apixaban-2018#ddi",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-apixaban-2018#vte",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
          "role": "support",
          "text": "NVAF: apixaban 5 mg BID; reduce to 2.5 mg BID if the patient has ≥2 of: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL."
        },
        {
          "chunk_id": "lexi-apixaban-2018#ddi",
          "role": "support",
          "text": "Avoid with strong dual CYP3A4/P-gp inhibitors/inducers; assess hepatic impairment."
        },
        {
          "chunk_id": "lexi-apixaban-2018#vte",
          "role": "distractor",
          "text": "VTE treatment: 10 mg BID x7 days then 5 mg BID—this regimen does not apply to NVAF dosing decisions."
        }
      ],
      "failure_analysis": {
        "question_id": "q004",
        "question": "Elderly patient with nonvalvular AF: 82 years, 58 kg, SCr 1.6 mg/dL. What apixaban dose?",
        "failure_types": [
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-apixaban-2018#ddi",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-apixaban-2018#vte",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-apixaban-2018#ddi",
          "lexi-apixaban-2018#dosing-nvaf"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":2.5,\"volume_per_dose_mL\":null,\"frequency\":\"q12h\",\"max_daily_mg\":5,\"rounding\":\"No rounding needed for tablet dose\",\"calc_rule\":\"Meets 2 of 3 criteria for dose reduction: age ≥80y (82y), weight ≤60kg (58kg), SCr ≥1.5mg/dL (1.6mg/dL)\",\"citations\":[\"lexi-apixaban-2018#dosing-nvaf\"],\"notes\":\"Reduced dose of 2.5mg tablets twice daily indicated due to meeting multiple criteria for dose reduction in NVAF.\"}",
        "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
        "key_points_missing": [
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.03287730234365174,
          "rouge_1_f1": 0.26804123711340205,
          "rouge_2_f1": 0.10526315789473684,
          "rouge_l_f1": 0.22680412371134018,
          "semantic_similarity": 0.4757928252220154,
          "key_points_covered": 0.25,
          "key_points_found": [
            "Dose reduction criteria (2 of 3)"
          ],
          "key_points_missing": [
            "Final dose 2.5 mg BID",
            "Interaction caveat: strong CYP3A4/P-gp",
            "Hepatic impairment caution"
          ],
          "answer_length": 39,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q005",
      "question": {
        "id": "q005",
        "question": "85 kg adult with acute DVT: What is the enoxaparin treatment dose (normal renal function)?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
        "answer_key_points": [
          "1 mg/kg q12h primary regimen",
          "Alternative 1.5 mg/kg q24h",
          "Per-dose 85 mg for 85 kg",
          "Renal adjustment for CrCl <30"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-enoxaparin-2018#dosing",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#renal",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "enoxaparin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 85,
          "doses_per_day": 2,
          "total_daily_mg": 170,
          "calc_rule": "1 mg/kg q12h (or 1.5 mg/kg q24h alternative)",
          "max_daily_mg": null,
          "renal_adjustment": "CrCl <30: 1 mg/kg once daily",
          "hepatic_adjustment": "use caution",
          "contraindications": [
            "active major bleeding",
            "history of HIT (use alternative)"
          ],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-enoxaparin-2018#dosing",
            "lexi-enoxaparin-2018#renal"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-enoxaparin-2018#dosing",
            "role": "support",
            "text": "Acute DVT treatment (normal renal function): enoxaparin 1 mg/kg SC q12h (preferred) or 1.5 mg/kg SC once daily (alternative)."
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#renal",
            "role": "support",
            "text": "If CrCl <30 mL/min, use 1 mg/kg SC once daily and monitor anti-Xa as indicated."
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#prophylaxis",
            "role": "distractor",
            "text": "VTE prophylaxis doses (e.g., 40 mg SC daily) are not treatment doses and should not be used here."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-enoxaparin-2018#dosing",
            "lexi-enoxaparin-2018#renal"
          ],
          "disallowed_chunk_ids": [
            "lexi-enoxaparin-2018#prophylaxis"
          ]
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":85,\"volume_per_dose_mL\":0.9,\"frequency\":\"q12h\",\"max_daily_mg\":170,\"rounding\":\"Round to nearest 0.1 mL based on 100 mg/mL concentration\",\"calc_rule\":\"1 mg/kg q12h (preferred regimen) x 85 kg = 85 mg per dose\",\"citations\":[\"lexi-enoxaparin-2018#dosing\"],\"notes\":\"Preferred regimen is 1 mg/kg q12h for acute DVT with normal renal function, with 1.5 mg/kg daily as an alternative.\"}",
      "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.03887336246346367,
        "rouge_1_f1": 0.4077669902912622,
        "rouge_2_f1": 0.21782178217821782,
        "rouge_l_f1": 0.2912621359223301,
        "semantic_similarity": 0.730822741985321,
        "key_points_covered": 0.75,
        "key_points_found": [
          "1 mg/kg q12h primary regimen",
          "Alternative 1.5 mg/kg q24h",
          "Per-dose 85 mg for 85 kg"
        ],
        "key_points_missing": [
          "Renal adjustment for CrCl <30"
        ],
        "answer_length": 41,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-enoxaparin-2018#dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#renal",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#prophylaxis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-enoxaparin-2018#dosing",
          "role": "support",
          "text": "Acute DVT treatment (normal renal function): enoxaparin 1 mg/kg SC q12h (preferred) or 1.5 mg/kg SC once daily (alternative)."
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#renal",
          "role": "support",
          "text": "If CrCl <30 mL/min, use 1 mg/kg SC once daily and monitor anti-Xa as indicated."
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#prophylaxis",
          "role": "distractor",
          "text": "VTE prophylaxis doses (e.g., 40 mg SC daily) are not treatment doses and should not be used here."
        }
      ],
      "failure_analysis": {
        "question_id": "q005",
        "question": "85 kg adult with acute DVT: What is the enoxaparin treatment dose (normal renal function)?",
        "failure_types": [
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-enoxaparin-2018#dosing",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#renal",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#prophylaxis",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-enoxaparin-2018#dosing",
          "lexi-enoxaparin-2018#renal"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":85,\"volume_per_dose_mL\":0.9,\"frequency\":\"q12h\",\"max_daily_mg\":170,\"rounding\":\"Round to nearest 0.1 mL based on 100 mg/mL concentration\",\"calc_rule\":\"1 mg/kg q12h (preferred regimen) x 85 kg = 85 mg per dose\",\"citations\":[\"lexi-enoxaparin-2018#dosing\"],\"notes\":\"Preferred regimen is 1 mg/kg q12h for acute DVT with normal renal function, with 1.5 mg/kg daily as an alternative.\"}",
        "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
        "key_points_missing": [
          "Renal adjustment for CrCl <30"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.03887336246346367,
          "rouge_1_f1": 0.4077669902912622,
          "rouge_2_f1": 0.21782178217821782,
          "rouge_l_f1": 0.2912621359223301,
          "semantic_similarity": 0.730822741985321,
          "key_points_covered": 0.75,
          "key_points_found": [
            "1 mg/kg q12h primary regimen",
            "Alternative 1.5 mg/kg q24h",
            "Per-dose 85 mg for 85 kg"
          ],
          "key_points_missing": [
            "Renal adjustment for CrCl <30"
          ],
          "answer_length": 41,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "medium",
        "notes": null
      }
    },
    {
      "question_id": "q006",
      "question": {
        "id": "q006",
        "question": "Type 2 diabetes patient with eGFR 28 mL/min/1.73 m². Can we use metformin?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
        "answer_key_points": [
          "Contraindicated if eGFR <30",
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-metformin-2018#renal",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-metformin-2018#contra",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "metformin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "decision": "contraindicated",
          "calc_rule": "eGFR <30 → do not initiate/continue",
          "renal_adjustment": "eGFR 30–45: avoid initiation; reduce if continuing; monitor",
          "hepatic_adjustment": "avoid in hepatic impairment",
          "contraindications": [
            "eGFR <30",
            "acute/chronic metabolic acidosis"
          ],
          "interactions": [
            {
              "drug": "iodinated contrast",
              "severity": "major",
              "action": "hold around procedure per eGFR"
            }
          ],
          "recency_risk": false,
          "citations": [
            "lexi-metformin-2018#renal",
            "lexi-metformin-2018#contra"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-metformin-2018#renal",
            "role": "support",
            "text": "Metformin: contraindicated if eGFR <30 mL/min/1.73 m². At 30–45, generally avoid initiation; if continuing, reduce dose and monitor renal function."
          },
          {
            "chunk_id": "lexi-metformin-2018#contra",
            "role": "support",
            "text": "Avoid in hepatic impairment or conditions predisposing to lactic acidosis; manage iodinated contrast per eGFR."
          },
          {
            "chunk_id": "lexi-metformin-2018#old-crcl60",
            "role": "distractor",
            "text": "Older conservative thresholds (e.g., avoid if CrCl <60) are superseded by eGFR-based guidance."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-metformin-2018#renal",
            "lexi-metformin-2018#contra"
          ],
          "disallowed_chunk_ids": [
            "lexi-metformin-2018#old-crcl60"
          ]
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"n/a\",\"max_daily_mg\":null,\"rounding\":\"n/a\",\"calc_rule\":\"eGFR <30 mL/min/1.73m² = contraindicated\",\"citations\":[\"lexi-metformin-2018#renal\"],\"notes\":\"Metformin is contraindicated in this patient with eGFR 28 mL/min/1.73m² due to risk of lactic acidosis.\"}",
      "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.013186148017665336,
        "rouge_1_f1": 0.13333333333333333,
        "rouge_2_f1": 0.027397260273972605,
        "rouge_l_f1": 0.08,
        "semantic_similarity": 0.5471715331077576,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Contraindicated if eGFR <30"
        ],
        "key_points_missing": [
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "answer_length": 20,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-metformin-2018#renal",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-metformin-2018#contra",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-metformin-2018#old-crcl60",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-metformin-2018#renal",
          "role": "support",
          "text": "Metformin: contraindicated if eGFR <30 mL/min/1.73 m². At 30–45, generally avoid initiation; if continuing, reduce dose and monitor renal function."
        },
        {
          "chunk_id": "lexi-metformin-2018#contra",
          "role": "support",
          "text": "Avoid in hepatic impairment or conditions predisposing to lactic acidosis; manage iodinated contrast per eGFR."
        },
        {
          "chunk_id": "lexi-metformin-2018#old-crcl60",
          "role": "distractor",
          "text": "Older conservative thresholds (e.g., avoid if CrCl <60) are superseded by eGFR-based guidance."
        }
      ],
      "failure_analysis": {
        "question_id": "q006",
        "question": "Type 2 diabetes patient with eGFR 28 mL/min/1.73 m². Can we use metformin?",
        "failure_types": [
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-metformin-2018#renal",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-metformin-2018#contra",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-metformin-2018#old-crcl60",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-metformin-2018#contra",
          "lexi-metformin-2018#renal"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"n/a\",\"max_daily_mg\":null,\"rounding\":\"n/a\",\"calc_rule\":\"eGFR <30 mL/min/1.73m² = contraindicated\",\"citations\":[\"lexi-metformin-2018#renal\"],\"notes\":\"Metformin is contraindicated in this patient with eGFR 28 mL/min/1.73m² due to risk of lactic acidosis.\"}",
        "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
        "key_points_missing": [
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.013186148017665336,
          "rouge_1_f1": 0.13333333333333333,
          "rouge_2_f1": 0.027397260273972605,
          "rouge_l_f1": 0.08,
          "semantic_similarity": 0.5471715331077576,
          "key_points_covered": 0.3333333333333333,
          "key_points_found": [
            "Contraindicated if eGFR <30"
          ],
          "key_points_missing": [
            "30–45: avoid initiation; if continuing, reduce & monitor",
            "Hepatic impairment: avoid (lactic acidosis risk)"
          ],
          "answer_length": 20,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q007",
      "question": {
        "id": "q007",
        "question": "Uncomplicated cystitis: Should we use nitrofurantoin if eGFR is 25?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
        "answer_key_points": [
          "Avoid if eGFR/CrCl <30",
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-nitrofurantoin-2018#renal",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#contra",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "nitrofurantoin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "decision": "avoid",
          "calc_rule": "Avoid if eGFR/CrCl <30",
          "renal_adjustment": "not recommended below threshold",
          "hepatic_adjustment": "use caution",
          "contraindications": [
            "CrCl <30",
            "late-term pregnancy (at term)"
          ],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-nitrofurantoin-2018#renal",
            "lexi-nitrofurantoin-2018#contra"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-nitrofurantoin-2018#renal",
            "role": "support",
            "text": "Nitrofurantoin: avoid when eGFR/CrCl <30 mL/min due to inadequate urinary concentrations and increased toxicity risk."
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#contra",
            "role": "support",
            "text": "Contraindications include late-term pregnancy (at term) and significant renal dysfunction."
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#prophylaxis",
            "role": "distractor",
            "text": "Prophylaxis regimens (e.g., low-dose at bedtime) do not override renal cutoffs for acute cystitis treatment."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-nitrofurantoin-2018#renal",
            "lexi-nitrofurantoin-2018#contra"
          ],
          "disallowed_chunk_ids": [
            "lexi-nitrofurantoin-2018#prophylaxis"
          ]
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"\",\"max_daily_mg\":null,\"rounding\":\"Not applicable - contraindicated\",\"calc_rule\":\"Contraindicated if eGFR <30 mL/min\",\"citations\":[\"lexi-nitrofurantoin-2018#renal\",\"lexi-nitrofurantoin-2018#contra\"],\"notes\":\"Nitrofurantoin is contraindicated at eGFR 25 mL/min due to inadequate urinary concentrations and increased toxicity risk.\"}",
      "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.023310461063598017,
        "rouge_1_f1": 0.3142857142857142,
        "rouge_2_f1": 0.14705882352941177,
        "rouge_l_f1": 0.2857142857142857,
        "semantic_similarity": 0.7304202914237976,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Avoid if eGFR/CrCl <30",
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "answer_length": 23,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-nitrofurantoin-2018#renal",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#contra",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#prophylaxis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-nitrofurantoin-2018#renal",
          "role": "support",
          "text": "Nitrofurantoin: avoid when eGFR/CrCl <30 mL/min due to inadequate urinary concentrations and increased toxicity risk."
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#contra",
          "role": "support",
          "text": "Contraindications include late-term pregnancy (at term) and significant renal dysfunction."
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#prophylaxis",
          "role": "distractor",
          "text": "Prophylaxis regimens (e.g., low-dose at bedtime) do not override renal cutoffs for acute cystitis treatment."
        }
      ],
      "failure_analysis": {
        "question_id": "q007",
        "question": "Uncomplicated cystitis: Should we use nitrofurantoin if eGFR is 25?",
        "failure_types": [
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-nitrofurantoin-2018#renal",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#contra",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#prophylaxis",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-nitrofurantoin-2018#contra",
          "lexi-nitrofurantoin-2018#renal"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"\",\"max_daily_mg\":null,\"rounding\":\"Not applicable - contraindicated\",\"calc_rule\":\"Contraindicated if eGFR <30 mL/min\",\"citations\":[\"lexi-nitrofurantoin-2018#renal\",\"lexi-nitrofurantoin-2018#contra\"],\"notes\":\"Nitrofurantoin is contraindicated at eGFR 25 mL/min due to inadequate urinary concentrations and increased toxicity risk.\"}",
        "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
        "key_points_missing": [
          "Avoid if eGFR/CrCl <30",
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.023310461063598017,
          "rouge_1_f1": 0.3142857142857142,
          "rouge_2_f1": 0.14705882352941177,
          "rouge_l_f1": 0.2857142857142857,
          "semantic_similarity": 0.7304202914237976,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Avoid if eGFR/CrCl <30",
            "Rationale: efficacy/toxicity",
            "List common contraindications where relevant"
          ],
          "answer_length": 23,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "medium",
        "notes": null
      }
    },
    {
      "question_id": "q008",
      "question": {
        "id": "q008",
        "question": "Patient on warfarin needs TMP-SMX for UTI. Any interaction and what should we do?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
        "answer_key_points": [
          "Mechanism: CYP2C9 inhibition + gut flora",
          "Severity: major",
          "Action: avoid or close INR monitoring with dose reduction"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "warfarin"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "trimethoprim/sulfamethoxazole",
              "mechanism": "CYP2C9 inhibition + gut flora change",
              "severity": "major",
              "action": "avoid if possible; otherwise increase INR monitoring and reduce warfarin dose"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-warfarin-2018#ddi-tmp-smx"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
            "role": "support",
            "text": "TMP-SMX markedly increases warfarin effect via CYP2C9 inhibition and gut-flora changes; expect INR rise. Prefer alternatives; if used, reduce warfarin dose and increase INR monitoring."
          },
          {
            "chunk_id": "lexi-warfarin-2018#ddi-cephalexin",
            "role": "distractor",
            "text": "Cephalexin has minimal effect on warfarin relative to TMP-SMX; management differs."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-warfarin-2018#ddi-tmp-smx"
          ],
          "disallowed_chunk_ids": [
            "lexi-warfarin-2018#ddi-cephalexin"
          ]
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"n/a\",\"max_daily_mg\":null,\"rounding\":\"n/a\",\"calc_rule\":\"Drug interaction via CYP2C9 inhibition and gut flora changes\",\"citations\":[\"lexi-warfarin-2018#ddi-tmp-smx\"],\"notes\":\"TMP-SMX markedly increases warfarin effect requiring warfarin dose reduction and increased INR monitoring, with preference for alternative antibiotics.\"}",
      "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.009203532683299362,
        "rouge_1_f1": 0.29333333333333333,
        "rouge_2_f1": 0.136986301369863,
        "rouge_l_f1": 0.21333333333333335,
        "semantic_similarity": 0.5828671455383301,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Mechanism: CYP2C9 inhibition + gut flora"
        ],
        "key_points_missing": [
          "Severity: major",
          "Action: avoid or close INR monitoring with dose reduction"
        ],
        "answer_length": 26,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-warfarin-2018#ddi-cephalexin",
          "score": 0.0,
          "rank": 2
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
          "role": "support",
          "text": "TMP-SMX markedly increases warfarin effect via CYP2C9 inhibition and gut-flora changes; expect INR rise. Prefer alternatives; if used, reduce warfarin dose and increase INR monitoring."
        },
        {
          "chunk_id": "lexi-warfarin-2018#ddi-cephalexin",
          "role": "distractor",
          "text": "Cephalexin has minimal effect on warfarin relative to TMP-SMX; management differs."
        }
      ],
      "failure_analysis": {
        "question_id": "q008",
        "question": "Patient on warfarin needs TMP-SMX for UTI. Any interaction and what should we do?",
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-warfarin-2018#ddi-cephalexin",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-warfarin-2018#ddi-tmp-smx"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"n/a\",\"max_daily_mg\":null,\"rounding\":\"n/a\",\"calc_rule\":\"Drug interaction via CYP2C9 inhibition and gut flora changes\",\"citations\":[\"lexi-warfarin-2018#ddi-tmp-smx\"],\"notes\":\"TMP-SMX markedly increases warfarin effect requiring warfarin dose reduction and increased INR monitoring, with preference for alternative antibiotics.\"}",
        "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
        "key_points_missing": [
          "Severity: major",
          "Action: avoid or close INR monitoring with dose reduction"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.5,
            "5": 0.5,
            "10": 0.5,
            "20": 0.5
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.009203532683299362,
          "rouge_1_f1": 0.29333333333333333,
          "rouge_2_f1": 0.136986301369863,
          "rouge_l_f1": 0.21333333333333335,
          "semantic_similarity": 0.5828671455383301,
          "key_points_covered": 0.3333333333333333,
          "key_points_found": [
            "Mechanism: CYP2C9 inhibition + gut flora"
          ],
          "key_points_missing": [
            "Severity: major",
            "Action: avoid or close INR monitoring with dose reduction"
          ],
          "answer_length": 26,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q009",
      "question": {
        "id": "q009",
        "question": "Patient on atorvastatin needs clarithromycin. What’s the risk and action?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
        "answer_key_points": [
          "Mechanism: strong CYP3A4 inhibition",
          "Severity: major",
          "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "atorvastatin"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "clarithromycin",
              "mechanism": "strong CYP3A4 inhibition",
              "severity": "major",
              "action": "avoid coadministration; if unavoidable, hold atorvastatin or use lowest dose with monitoring"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-atorvastatin-2018#ddi-macrolides"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
            "role": "support",
            "text": "Clarithromycin is a strong CYP3A4 inhibitor; coadministration increases atorvastatin levels and myopathy/rhabdomyolysis risk. Avoid; if unavoidable, hold or use the lowest dose with close monitoring."
          },
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-azithro",
            "role": "distractor",
            "text": "Azithromycin has little CYP3A4 inhibition and is not a suitable proxy for clarithromycin interactions."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-atorvastatin-2018#ddi-macrolides"
          ],
          "disallowed_chunk_ids": [
            "lexi-atorvastatin-2018#ddi-azithro"
          ]
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"hold\",\"max_daily_mg\":null,\"rounding\":\"not applicable\",\"calc_rule\":\"hold atorvastatin during clarithromycin due to CYP3A4 inhibition; if unavoidable use lowest dose with monitoring\",\"citations\":[\"lexi-atorvastatin-2018#ddi-macrolides\"],\"notes\":\"Major interaction increases myopathy/rhabdomyolysis risk through strong CYP3A4 inhibition.\"}",
      "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.01968294124523931,
        "rouge_1_f1": 0.35135135135135137,
        "rouge_2_f1": 0.1388888888888889,
        "rouge_l_f1": 0.18918918918918917,
        "semantic_similarity": 0.6204959154129028,
        "key_points_covered": 0.6666666666666666,
        "key_points_found": [
          "Mechanism: strong CYP3A4 inhibition",
          "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
        ],
        "key_points_missing": [
          "Severity: major"
        ],
        "answer_length": 24,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-azithro",
          "score": 0.0,
          "rank": 2
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
          "role": "support",
          "text": "Clarithromycin is a strong CYP3A4 inhibitor; coadministration increases atorvastatin levels and myopathy/rhabdomyolysis risk. Avoid; if unavoidable, hold or use the lowest dose with close monitoring."
        },
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-azithro",
          "role": "distractor",
          "text": "Azithromycin has little CYP3A4 inhibition and is not a suitable proxy for clarithromycin interactions."
        }
      ],
      "failure_analysis": {
        "question_id": "q009",
        "question": "Patient on atorvastatin needs clarithromycin. What’s the risk and action?",
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-azithro",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-atorvastatin-2018#ddi-macrolides"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"hold\",\"max_daily_mg\":null,\"rounding\":\"not applicable\",\"calc_rule\":\"hold atorvastatin during clarithromycin due to CYP3A4 inhibition; if unavoidable use lowest dose with monitoring\",\"citations\":[\"lexi-atorvastatin-2018#ddi-macrolides\"],\"notes\":\"Major interaction increases myopathy/rhabdomyolysis risk through strong CYP3A4 inhibition.\"}",
        "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
        "key_points_missing": [
          "Severity: major"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.5,
            "5": 0.5,
            "10": 0.5,
            "20": 0.5
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.01968294124523931,
          "rouge_1_f1": 0.35135135135135137,
          "rouge_2_f1": 0.1388888888888889,
          "rouge_l_f1": 0.18918918918918917,
          "semantic_similarity": 0.6204959154129028,
          "key_points_covered": 0.6666666666666666,
          "key_points_found": [
            "Mechanism: strong CYP3A4 inhibition",
            "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
          ],
          "key_points_missing": [
            "Severity: major"
          ],
          "answer_length": 24,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q010",
      "question": {
        "id": "q010",
        "question": "Starting linezolid in a patient on sertraline. Is this safe?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
        "answer_key_points": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-linezolid-2018#ddi-ssri",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "linezolid"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "sertraline (SSRI)",
              "mechanism": "MAOI activity of linezolid → ↑serotonin",
              "severity": "major",
              "action": "avoid combination; if unavoidable, withhold SSRI or monitor closely"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-linezolid-2018#ddi-ssri"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-linezolid-2018#ddi-ssri",
            "role": "support",
            "text": "Linezolid has reversible MAOI activity and may precipitate serotonin syndrome with SSRIs. Avoid combination; if benefits outweigh risks, withhold SSRI and monitor closely."
          },
          {
            "chunk_id": "lexi-linezolid-2018#ddi-penicillins",
            "role": "distractor",
            "text": "No serotonergic interaction with penicillins; this is not relevant to SSRI risk."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-linezolid-2018#ddi-ssri"
          ],
          "disallowed_chunk_ids": [
            "lexi-linezolid-2018#ddi-penicillins"
          ]
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"n/a\",\"max_daily_mg\":null,\"rounding\":\"n/a\",\"calc_rule\":\"Contraindicated due to MAOI activity unless benefits outweigh risks\",\"citations\":[\"lexi-linezolid-2018#ddi-ssri\"],\"notes\":\"Avoid combination due to serotonin syndrome risk; if necessary, withhold SSRI and monitor closely.\"}",
      "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.02709687095237191,
        "rouge_1_f1": 0.410958904109589,
        "rouge_2_f1": 0.14084507042253522,
        "rouge_l_f1": 0.24657534246575344,
        "semantic_similarity": 0.5318275094032288,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "answer_length": 22,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-linezolid-2018#ddi-ssri",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-linezolid-2018#ddi-penicillins",
          "score": 0.0,
          "rank": 2
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-linezolid-2018#ddi-ssri",
          "role": "support",
          "text": "Linezolid has reversible MAOI activity and may precipitate serotonin syndrome with SSRIs. Avoid combination; if benefits outweigh risks, withhold SSRI and monitor closely."
        },
        {
          "chunk_id": "lexi-linezolid-2018#ddi-penicillins",
          "role": "distractor",
          "text": "No serotonergic interaction with penicillins; this is not relevant to SSRI risk."
        }
      ],
      "failure_analysis": {
        "question_id": "q010",
        "question": "Starting linezolid in a patient on sertraline. Is this safe?",
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-linezolid-2018#ddi-ssri",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-linezolid-2018#ddi-penicillins",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-linezolid-2018#ddi-ssri"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"n/a\",\"max_daily_mg\":null,\"rounding\":\"n/a\",\"calc_rule\":\"Contraindicated due to MAOI activity unless benefits outweigh risks\",\"citations\":[\"lexi-linezolid-2018#ddi-ssri\"],\"notes\":\"Avoid combination due to serotonin syndrome risk; if necessary, withhold SSRI and monitor closely.\"}",
        "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
        "key_points_missing": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.5,
            "5": 0.5,
            "10": 0.5,
            "20": 0.5
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.02709687095237191,
          "rouge_1_f1": 0.410958904109589,
          "rouge_2_f1": 0.14084507042253522,
          "rouge_l_f1": 0.24657534246575344,
          "semantic_similarity": 0.5318275094032288,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Mechanism: MAOI activity → ↑serotonin",
            "Severity: major",
            "Action: avoid; or stop SSRI/close monitoring if unavoidable"
          ],
          "answer_length": 22,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q011",
      "question": {
        "id": "q011",
        "question": "Patient on digoxin will start amiodarone. What’s the interaction management?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
        "answer_key_points": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major",
          "Action: reduce dose ~30–50% + monitor levels and ECG"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-digoxin-2018#ddi-amio",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "digoxin"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "amiodarone",
              "mechanism": "P-gp inhibition → ↑digoxin levels",
              "severity": "major",
              "action": "reduce digoxin dose by ~30–50% and monitor serum levels and ECG"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-digoxin-2018#ddi-amio"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-digoxin-2018#ddi-amio",
            "role": "support",
            "text": "Amiodarone inhibits P-gp, increasing digoxin exposure. Reduce digoxin dose by ~30–50% and monitor serum levels, renal function, and ECG."
          },
          {
            "chunk_id": "lexi-digoxin-2018#ddi-verapamil",
            "role": "distractor",
            "text": "Verapamil also raises digoxin via P-gp inhibition, but this does not address amiodarone-specific management."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-digoxin-2018#ddi-amio"
          ],
          "disallowed_chunk_ids": [
            "lexi-digoxin-2018#ddi-verapamil"
          ]
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"maintain current\",\"max_daily_mg\":null,\"rounding\":\"reduce current dose by 30-50%\",\"calc_rule\":\"reduce existing digoxin dose by 30-50% due to P-glycoprotein inhibition\",\"citations\":[\"lexi-digoxin-2018#ddi-amio\"],\"notes\":\"Reduce digoxin dose by 30-50% when starting amiodarone and monitor digoxin levels, renal function, and ECG.\"}",
      "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.030188043146318764,
        "rouge_1_f1": 0.3116883116883117,
        "rouge_2_f1": 0.16000000000000003,
        "rouge_l_f1": 0.3116883116883117,
        "semantic_similarity": 0.7014154195785522,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Action: reduce dose ~30–50% + monitor levels and ECG"
        ],
        "key_points_missing": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major"
        ],
        "answer_length": 30,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-digoxin-2018#ddi-amio",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-digoxin-2018#ddi-verapamil",
          "score": 0.0,
          "rank": 2
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-digoxin-2018#ddi-amio",
          "role": "support",
          "text": "Amiodarone inhibits P-gp, increasing digoxin exposure. Reduce digoxin dose by ~30–50% and monitor serum levels, renal function, and ECG."
        },
        {
          "chunk_id": "lexi-digoxin-2018#ddi-verapamil",
          "role": "distractor",
          "text": "Verapamil also raises digoxin via P-gp inhibition, but this does not address amiodarone-specific management."
        }
      ],
      "failure_analysis": {
        "question_id": "q011",
        "question": "Patient on digoxin will start amiodarone. What’s the interaction management?",
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-digoxin-2018#ddi-amio",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-digoxin-2018#ddi-verapamil",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-digoxin-2018#ddi-amio"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"maintain current\",\"max_daily_mg\":null,\"rounding\":\"reduce current dose by 30-50%\",\"calc_rule\":\"reduce existing digoxin dose by 30-50% due to P-glycoprotein inhibition\",\"citations\":[\"lexi-digoxin-2018#ddi-amio\"],\"notes\":\"Reduce digoxin dose by 30-50% when starting amiodarone and monitor digoxin levels, renal function, and ECG.\"}",
        "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
        "key_points_missing": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.5,
            "5": 0.5,
            "10": 0.5,
            "20": 0.5
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.030188043146318764,
          "rouge_1_f1": 0.3116883116883117,
          "rouge_2_f1": 0.16000000000000003,
          "rouge_l_f1": 0.3116883116883117,
          "semantic_similarity": 0.7014154195785522,
          "key_points_covered": 0.3333333333333333,
          "key_points_found": [
            "Action: reduce dose ~30–50% + monitor levels and ECG"
          ],
          "key_points_missing": [
            "Mechanism: P-gp inhibition → ↑digoxin",
            "Severity: major"
          ],
          "answer_length": 30,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "medium",
        "notes": null
      }
    },
    {
      "question_id": "q012",
      "question": {
        "id": "q012",
        "question": "COVID-19 patient asks for Paxlovid dosing and interaction checks.",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
        "answer_key_points": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "relevant_chunks": [],
        "drug_names": [
          "nirmatrelvir/ritonavir (Paxlovid)"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "abstain_expected": true,
          "reason": "Not present in ≤2018 corpus; recency-sensitive",
          "recency_risk": true,
          "citations": []
        },
        "oracle_context": [
          {
            "chunk_id": "kb-scope-2018#covid-absent",
            "role": "support",
            "text": "The corpus predates COVID-19 therapies (e.g., nirmatrelvir/ritonavir). This is recency-sensitive; abstain and refer to current guidance/pharmacist."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "kb-scope-2018#covid-absent"
          ],
          "disallowed_chunk_ids": []
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"\",\"max_daily_mg\":null,\"rounding\":\"Not applicable - insufficient data\",\"calc_rule\":\"Cannot calculate - predates COVID-19 therapies\",\"citations\":[\"kb-scope-2018#covid-absent\"],\"notes\":\"Knowledge base predates COVID-19 therapies including Paxlovid (nirmatrelvir/ritonavir); refer to current clinical guidance and pharmacist.\"}",
      "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 0,
        "total_essential": 0
      },
      "qa_metrics": {
        "bleu_score": 0.0028418842662913846,
        "rouge_1_f1": 0.18461538461538463,
        "rouge_2_f1": 0.0,
        "rouge_l_f1": 0.18461538461538463,
        "semantic_similarity": 0.40756627917289734,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "answer_length": 24,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "kb-scope-2018#covid-absent",
          "score": 0.0,
          "rank": 1
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "kb-scope-2018#covid-absent",
          "role": "support",
          "text": "The corpus predates COVID-19 therapies (e.g., nirmatrelvir/ritonavir). This is recency-sensitive; abstain and refer to current guidance/pharmacist."
        }
      ],
      "failure_analysis": {
        "question_id": "q012",
        "question": "COVID-19 patient asks for Paxlovid dosing and interaction checks.",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "kb-scope-2018#covid-absent",
            "score": 0.0,
            "rank": 1
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"\",\"max_daily_mg\":null,\"rounding\":\"Not applicable - insufficient data\",\"calc_rule\":\"Cannot calculate - predates COVID-19 therapies\",\"citations\":[\"kb-scope-2018#covid-absent\"],\"notes\":\"Knowledge base predates COVID-19 therapies including Paxlovid (nirmatrelvir/ritonavir); refer to current clinical guidance and pharmacist.\"}",
        "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
        "key_points_missing": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 0,
          "total_essential": 0
        },
        "qa_metrics": {
          "bleu_score": 0.0028418842662913846,
          "rouge_1_f1": 0.18461538461538463,
          "rouge_2_f1": 0.0,
          "rouge_l_f1": 0.18461538461538463,
          "semantic_similarity": 0.40756627917289734,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Explicit abstention",
            "Sets recency_risk = true",
            "Advises pharmacist/current guidance"
          ],
          "answer_length": 24,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q013",
      "question": {
        "id": "q013",
        "question": "What is the current first-line pharmacologic therapy per latest hypertension guidelines?",
        "question_type": "guideline",
        "difficulty": "medium",
        "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
        "answer_key_points": [
          "Explicit abstention for ‘current’ guideline ask",
          "Recognize JNC8 (2014) is outdated for ‘current’",
          "Sets recency_risk = true"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-hypertension-2014#jnc8",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [],
        "tags": [
          "guideline"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "abstain_expected": true,
          "reason": "Question seeks guidance newer than 2018; corpus includes JNC8 (2014) only",
          "recency_risk": true,
          "citations": [
            "lexi-hypertension-2014#jnc8"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-hypertension-2014#jnc8",
            "role": "support",
            "text": "Corpus contains JNC8 (2014) content. If the question asks for the *current* guideline, abstain and flag recency risk rather than quoting outdated recommendations."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-hypertension-2014#jnc8"
          ],
          "disallowed_chunk_ids": []
        }
      },
      "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"\",\"max_daily_mg\":null,\"rounding\":\"Not applicable\",\"calc_rule\":\"No current dosing available\",\"citations\":[\"lexi-hypertension-2014#jnc8\"],\"notes\":\"Cannot provide current first-line therapy as available guideline data from JNC8 (2014) is outdated.\"}",
      "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0030860166165309253,
        "rouge_1_f1": 0.10169491525423728,
        "rouge_2_f1": 0.03508771929824561,
        "rouge_l_f1": 0.10169491525423728,
        "semantic_similarity": 0.2578904330730438,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Explicit abstention for ‘current’ guideline ask",
          "Recognize JNC8 (2014) is outdated for ‘current’",
          "Sets recency_risk = true"
        ],
        "answer_length": 18,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-hypertension-2014#jnc8",
          "score": 0.0,
          "rank": 1
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-hypertension-2014#jnc8",
          "role": "support",
          "text": "Corpus contains JNC8 (2014) content. If the question asks for the *current* guideline, abstain and flag recency risk rather than quoting outdated recommendations."
        }
      ],
      "failure_analysis": {
        "question_id": "q013",
        "question": "What is the current first-line pharmacologic therapy per latest hypertension guidelines?",
        "failure_types": [
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-hypertension-2014#jnc8",
            "score": 0.0,
            "rank": 1
          }
        ],
        "relevant_chunks_found": [
          "lexi-hypertension-2014#jnc8"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"\",\"max_daily_mg\":null,\"rounding\":\"Not applicable\",\"calc_rule\":\"No current dosing available\",\"citations\":[\"lexi-hypertension-2014#jnc8\"],\"notes\":\"Cannot provide current first-line therapy as available guideline data from JNC8 (2014) is outdated.\"}",
        "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
        "key_points_missing": [
          "Explicit abstention for ‘current’ guideline ask",
          "Recognize JNC8 (2014) is outdated for ‘current’",
          "Sets recency_risk = true"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.0030860166165309253,
          "rouge_1_f1": 0.10169491525423728,
          "rouge_2_f1": 0.03508771929824561,
          "rouge_l_f1": 0.10169491525423728,
          "semantic_similarity": 0.2578904330730438,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Explicit abstention for ‘current’ guideline ask",
            "Recognize JNC8 (2014) is outdated for ‘current’",
            "Sets recency_risk = true"
          ],
          "answer_length": 18,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "high",
        "notes": null
      }
    }
  ]
}